Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: Case report

Prostate

Volumn 38, Issue 4, 1999, Pages 313-316

  Koutsilieris, Michael ^a   Tzanela, Marinella ^a   Dimopoulos, Theodoros ^b  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b PANAGIA GENERAL HOSPITAL   (Greece)

Author keywords

Apoptosis; Osteoblastic metastasis; Prostate cancer; Stage D3; Survival factors

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ALKALINE PHOSPHATASE; ANGIOPEPTIN; BICALUTAMIDE; DEXAMETHASONE; ESTRAMUSTINE PHOSPHATE; FLUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; TRIPTORELIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CASE REPORT; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; ORCHIECTOMY; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CARCINOMA;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ESTRAMUSTINE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; SOMATOSTATIN; TRIPTORELIN;

EID: 0033106316     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990301)38:4<313::AID-PROS7>3.0.CO;2-8     Document Type: Article

References (19)

1. Kozlowski JM, Ellis WJ, Grayhack JT. Advanced prostatic carcinoma: early vs. late endocrine therapy. Urol Clin North Am 1991;15-24.
2. Mertens WC, Stitt L, Porter AT. Strodium 89 therapy and relief of pain in patients with prostatic carcinoma metastatic to bone: a dose response relationship. Am J Clin Oncol 1993;16:238-242.
3. Tubiana-Hulin M. Traitement hormonal des metastases osseuses des cancers. Rev Rheum 1990;57:821-827.
4. Koutsilieris M. Skeletal metastasis in advanced prostate cancer: cell biology and therapy. Crit Rev Oncol Hematol 1995;18:51-64.
5. Landstrom M, Damber JE, Bergh A. Regrowth after initially successful castration therapy may be related to decreased apoptotic cell death rate. Anticancer Res 1994;54:4281-4284.
6. Reyes-Moreno C, Sourla A, Choki I, Doillon C, Koutsilieris M. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin-apoptosis. Urology 1998;52: 341-347.
7. Reyes-Moreno C, Frenette G, Lavergne E, Boulanger J, Govindan MV, Koutsilieris M. Mediation of glucocorticoid receptor function by transforming growth factor beta 1 (TGFb1) expression in human PC-3 prostate cancer cells. Prostate 1995;26:260-269.
8. Boulanger J, Reyes-Moreno C, Koutsilieris M. Mediation of the glucocorticoid receptor function by the activation of latent transforming growth factor beta 1 in MG-63 osteoblast-like osteosarcoma cells. Int J Cancer 1995;61:692-697.
9. Delany AM, Canalis E. Transcriptional regression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology 1995;136:4776-4778.
10. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Polychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993;13: 481-486.
11. Reyes-Moreno C, Koutsilieris M. Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat bone. Clin Exp Metastasis 1997;15:205-217.
12. Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three years follow-up of acromegalic patients treatment with intramuscular slow-release lanreotide. J Clin Endocrinol Metab 1997;82:18-22.
13. Koutsilieris M, Dimopoulos MA, Doillon C, Sourla A, Reyes-Moreno C, Choki I. The molecular concept of prostate cancer. Cancer J 1996;9:89-94.
14. Koutsilieris M, Faure N, Laroche B, Tolis G, Roberts G, Ackman CFD. Objective response and disease outcome in 59 patients with stage D2 prostatic carcinoma treated with either buserelin or orchiectomy: disease aggressivity and its association with response and outcome. Urology 1986;27:221-227.
15. Galasco CSB. Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 1982;12:20-27.
16. Koutsilieris M, Rabbani SA, Bennett HPJ, Goltzman D. Characteristics of prostate-derived growth factors for cells of the osteoblast phenotype. J Clin Invest 1987;80:941-946.
17. Parrizas M, Leroith D. Insulin-like growth factor-1 inhibition of apoptosis is associated with increased expression of bcl-xL gene product. Endocrinology 1997;138:1355-1358.
18. Gajewski TF, Thompson CB. Apoptosis meets signal transduction: elimination of a BAD influence. Cell 1996;86:589-592.
19. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Biol Med 1998;217:143-152.